Ningning Yan

765 total citations
41 papers, 549 citations indexed

About

Ningning Yan is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ningning Yan has authored 41 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Ningning Yan's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Circular RNAs in diseases (5 papers). Ningning Yan is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Circular RNAs in diseases (5 papers). Ningning Yan collaborates with scholars based in China, Netherlands and Taiwan. Ningning Yan's co-authors include Liang Xu, Fengchun Zhang, Xiaochun Fei, Le Zhang, Xingya Li, Yanyun Zhang, Yingchun Xu, Sanxing Guo, Xiaobo Wu and Shujing Liang and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Annals of Oncology and Gene.

In The Last Decade

Ningning Yan

37 papers receiving 534 citations

Peers

Ningning Yan
Yejun Qin China
Liping Chung Australia
Christine A. Koch-Paiz United States
Elena Panizza United States
Chuanpeng Dong United States
Нуршат Гайфуллин Russia
Esra Göv Türkiye
Renjie Jin United States
Emma McCullagh United States
Yejun Qin China
Ningning Yan
Citations per year, relative to Ningning Yan Ningning Yan (= 1×) peers Yejun Qin

Countries citing papers authored by Ningning Yan

Since Specialization
Citations

This map shows the geographic impact of Ningning Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ningning Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ningning Yan more than expected).

Fields of papers citing papers by Ningning Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ningning Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ningning Yan. The network helps show where Ningning Yan may publish in the future.

Co-authorship network of co-authors of Ningning Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Ningning Yan. A scholar is included among the top collaborators of Ningning Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ningning Yan. Ningning Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guo, Sanxing, et al.. (2024). Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study. Frontiers in Oncology. 14. 1391828–1391828. 2 indexed citations
2.
Chen, Yihan, et al.. (2024). Effect of fibroblasts small- conductance Ca2+ -activated potassium channel subtype 2 (SK2) on myocardial fibrosis in pressure overload mouse. Cellular Signalling. 124. 111401–111401. 1 indexed citations
3.
Huang, Siyuan, Ningning Yan, Qianqian Guo, et al.. (2024). Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment. Frontiers in Oncology. 14. 1331387–1331387. 1 indexed citations
4.
Yan, Ningning, Huixian Zhang, Sanxing Guo, et al.. (2024). Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data. Frontiers in Oncology. 14. 1353491–1353491. 1 indexed citations
5.
6.
7.
8.
Yan, Ningning, Siyuan Huang, Lin Li, et al.. (2022). Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report. Frontiers in Pharmacology. 13. 898623–898623. 3 indexed citations
9.
10.
Wang, Jian, et al.. (2021). Study on digital twin channel for the B5G and 6G communication. 36(3). 16 indexed citations
11.
Li, Mingjun, et al.. (2020). Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6. Cancer Cell International. 20(1). 574–574. 25 indexed citations
12.
Dong, Junjian, Jia Li, Jie Hu, et al.. (2020). Comparative Genomics Studies on the dmrt Gene Family in Fish. Frontiers in Genetics. 11. 563947–563947. 26 indexed citations
13.
Yan, Ningning, et al.. (2020). Genome-wide identification of small G protein ROPs and their potential roles in Solanaceous family. Gene. 753. 144809–144809. 4 indexed citations
14.
Yan, Ningning, Jie Hu, Jia Li, et al.. (2019). Genomic organization and sexually dimorphic expression of the Dmrt1 gene in largemouth bass (Micropterus salmoides). Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology. 234. 68–77. 17 indexed citations
15.
Jiang, Longying, Hudie Wei, Ningning Yan, et al.. (2019). Structural basis of NR4A1 bound to the human pituitary proopiomelanocortin gene promoter. Biochemical and Biophysical Research Communications. 523(1). 1–5. 7 indexed citations
16.
Xu, Liang, Ningning Yan, Zhihua Li, et al.. (2018). A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis. OncoTargets and Therapy. Volume 11. 8389–8398. 5 indexed citations
17.
Yan, Ningning, Liang Xu, Xiaobo Wu, et al.. (2017). GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Experimental Cell Research. 359(2). 405–414. 66 indexed citations
18.
Yan, Ningning, et al.. (2017). GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Annals of Oncology. 28. v2–v3. 3 indexed citations
19.
Xu, Liang, Le Zhang, Chun Hu, et al.. (2016). WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. International Journal of Oncology. 48(3). 1175–1186. 82 indexed citations
20.
Dai, Lei, Cheng Li, Xuchen Zhang, et al.. (2011). Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice. Neoplasma. 58(6). 538–547. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yejun Qin Breakdown of academic impact, for papers by Liping Chung Breakdown of academic impact, for papers by Christine A. Koch-Paiz Breakdown of academic impact, for papers by Elena Panizza Breakdown of academic impact, for papers by Chuanpeng Dong Breakdown of academic impact, for papers by Нуршат Гайфуллин Breakdown of academic impact, for papers by Esra Göv Breakdown of academic impact, for papers by Renjie Jin Breakdown of academic impact, for papers by Emma McCullagh
Rankless by CCL
2026